Below are some of the key findings from the neuroblastoma drugs market analysis:
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.
Get a FREE sample now!
Global Neuroblastoma Drugs Industry Overview
Cancer research organizations are working extensively towards the identification of therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth. In case of patients suffering from neuroblastoma, a cell surface antigen, GD2 (O-acetyl-GD2 ganglioside), is observed to be overexpressed. This is encouraging researchers to come up with specific monoclonal antibodies against GD2. The growing demand for anti-GD2 antibodies is one of the critical reasons that will drive the neuroblastoma drugs market’s growth. An anti-GD2-specific monoclonal antibody called Dinutuximab was the first drug approved for the treatment of neuroblastoma. The increasing sales of anti-GD2 drugs are due to site-specific action of these drugs and they do not pose any cytotoxic effects in the body. Chemotherapy has harmful cytotoxic side effects which will impact the quality of life of neuroblastoma patients. Hence, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma. These factors are driving the growth of neuroblastoma drugs market during the forecast period.
The continual focus on identifying several new tumor targets through improved research of the etiology of neuroblastoma has resulted in the development of novel therapies for the treatment of relapsed refractory neuroblastoma. It is a fatal condition where a patient’s neuroblastoma returns or becomes unresponsive to the treatment. The study of new tumor targets enables the development of novel-antibodies and cell-mediated immunotherapy agents for the condition. This will drive the neuroblastoma drugs market to grow at a CAGR of over 4% during the forecast period. CUDC-904, Ch14.18, and 1311-MIBG are some of the novel therapies under research and development for neuroblastoma.
Top companies covered in the neuroblastoma drugs market research report
The neuroblastoma drugs market is moderately concentrated. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, the industry analysis report will allow clients to identify new growth opportunities and design innovative strategies to improve their share in the market.
The report offers a complete analysis of various companies including:
- Bristol-Myers Squibb
- Johnson & Johnson
- Pfizer
- Teva Pharmaceutical
- United Therapeutics
Neuroblastoma drugs market segmentation based on geographic regions
- Asia
- Europe
- North America
- ROW
North America will contribute to the highest market share throughout the forecast period. The increasing incidence of neuroblastoma, availability of reimbursement schemes and new drug approvals for the treatment of neuroblastoma are factors responsible for the high growth of the neuroblastoma drugs market in the region.
Neuroblastoma drugs market segmentation based on product
- Chemotherapy
- Immunotherapy
- Others
The chemotherapy segment accounted for the highest market share in the neuroblastoma drugs market. This can be attributed to the inherent advantages of drugs which involve site-specific action. However, the market share of the segment is expected to decline in the forthcoming years due to the harmful cytotoxicity-related side-effects of chemotherapy.
Key highlights of the global neuroblastoma drugs market for the forecast years 2019-2023:
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the neuroblastoma drugs market during the next five years
- Precise estimation of the global neuroblastoma drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the industry across various geographies such as Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of the companies
We can help! Our analysts can customize the market research report to meet your requirements. Get in touch